[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sinovac Biotech Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":368},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,73,92,109,127,153,179,206,228,253,274,299,320,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637880","phase-3-protective-efficacy--immunogenicity-and-safety-of-the-tetravalent-inactivated-enterovirus-vaccine-vero-cell-100637880",false,"NCT07611513","Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).","Multicenter, Randomized, Double-blind, Placebo-Controlled Phase IIIa Clinical Trial on the Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children Aged 6 to 71 Months.","Inclusion Criteria:\n\n1. Healthy children aged 6 to 71 months.\n2. Guardians who can understand and voluntarily sign the informed consent form\n3. Willing and able to comply with all visit schedules, sample collection, vaccinations, and other trial procedures。\n4. Provide legal identification for the participant and their guardian\n\nExclusion Criteria:\n\n1. A known history of HFMD\u002FHA\n2. Uncontrolled chronic diseases or a history of severe illnesses, including but not limited to cardiovascular diseases, blood disorders, liver or kidney diseases, digestive system diseases, respiratory system diseases, malignant tumors, or a history of major functional organ transplantation.\n3. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection).\n4. Abnormal coagulation function (such as coagulation factor deficiencies,and platelet abnormalities).\n5. Suffering from\u002Fhaving a history of severe neurological diseases (epilepsy, convulsions, or seizures \\[excluding a history of febrile seizures\\]) ,psychiatric disorders, or a family history of psychiatric disorders\n6. Various acute diseases or exacerbations of chronic diseases within the last 3 days.\n7. Having been vaccinated with a vaccine containing any of the components EV71, CA16, CA10, CA6.\n8. Having received ≥14 days of immunosuppressive or other immunomodulatory treatment (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent; local or inhaled corticosteroids excluded) within the past 6 months, or cytotoxic treatment, or planning to receive such treatment during the trial.\n9. Having received immunoglobulin or other blood products(excluding hepatitis B immunoglobulin) within the past 6 months, or planning to receive such treatment during the trial.\n10. Having received other investigational drugs or vaccines within the past 30 days, or planning to receive such drugs or vaccines during the trial.\n11. Having received live attenuated vaccines or nucleic acid vaccines within the past 14 days, or subunit or inactivated vaccines within the past 7 days.\n12. Known allergy to any component of the investigational vaccine (inactivated EV71 virus, inactivated CA16 virus, , inactivated CA10 virus,, inactivated CA6 virus,aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, injectable water).\n13. On the day of planned vaccination with the investigational vaccine, having an axillary temperature ≥37.3°C before vaccination, or other vital sign measurements outside the normal range,or the physical examination is not qualified.\n14. According to the investigator's judgment, participants have any other factors that make them unsuitable for participation in the clinical trial.",true,"ALL","6 Months","71 Months",{"count":21,"type":22},6000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children aged 6 to 71 months.\n\nParticipants will be randomly assigned in a 1:1 ratio to the trial group and the placebo group, receiving two doses of experimental vaccine or placebo , with a one-month interval between the two doses.",[28,29],"Hand, Foot, and Mouth Disease(HFMD)","Herpangina",[31,29,32,33,34,35],"Hand, Foot, and Mouth Disease (HFMD)","phase IIIa","immunogenicity","safety","protective efficacy","NOT_YET_RECRUITING","2026-05-22",{"date":39,"type":40},"2026-05-28","ACTUAL",{"date":42,"type":22},"2026-05",{"date":44,"type":22},"2028-09",{"name":46,"class":47},"Sinovac Biotech Co., Ltd","INDUSTRY",5,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100631838","phase-3-phase--trial-of-group-acyw135-meningococcal-conjugate-vaccine-in-children-aged-2-6-years-100631838","NCT07505888","Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years","A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 2-6 Years","Inclusion Criteria:\n\n1. Healthy participants aged 2 to 6 years.\n2. The participant's legal guardian is capable of understanding and voluntarily signs the informed consent form.\n3. Willing and able to comply with all scheduled visits, sample collection, vaccination, and other trial procedures.\n4. Provision of legal identification documentation.\n\nExclusion Criteria:\n\n1. History (or suspected history) of meningococcal disease.\n2. History of infantile wheezing\u002Fasthma; history of allergy to the vaccine or any vaccine components (Group A\u002FC\u002FY\u002FW135 meningococcal capsular polysaccharide, mannitol, sucrose, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, water for injection), such as urticaria, dyspnea, angioedema; or other serious adverse reactions following prior vaccination.\n3. Prior vaccination with Group A or Group A\u002FC meningococcal polysaccharide vaccine with an interval ≤1 year since the most recent dose; prior vaccination with any meningococcal polysaccharide\u002Fpolysaccharide conjugate vaccine other than Group A or Group A\u002FC meningococcal polysaccharide vaccines (including but not limited to: ACYW135 meningococcal polysaccharide vaccine, Group A\u002FC meningococcal polysaccharide conjugate vaccine, ACYW135 meningococcal polysaccharide conjugate vaccine).\n4. Presence of autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection in the participant or the participant's mother).\n5. Coagulation disorders (e.g., coagulation factor deficiency, platelet abnormalities) or history of significant bleeding, hematoma, or ecchymosis following intramuscular injection or venipuncture.\n6. Presence of poorly controlled chronic diseases or history of serious illnesses, including but not limited to cardiovascular diseases, metabolic diseases, hematological diseases, hepatorenal diseases, gastrointestinal diseases, respiratory diseases, malignancies, or history of major organ transplantation.\n7. Severe congenital anomalies, genetic defects, or malnutrition.\n8. Presence of or history of severe neurological disorders \\[epilepsy, convulsions or seizures (excluding history of febrile seizures)\\] or psychiatric disorders, or family history of psychiatric disorders.\n9. Receipt of immunoglobulins or other blood products within 3 months prior to enrollment, or planned receipt of such treatments during the trial period.\n10. Receipt of immunosuppressants or other immunomodulatory therapy for ≥14 days (e.g., prednisone ≥20 mg\u002Fday or ≥2 mg\u002Fkg\u002Fday, or equivalent), cytotoxic therapy within 6 months prior to enrollment, or planned receipt of such therapies during the study period.\n11. Receipt of any other investigational drug or vaccine within 3 months prior to enrollment, or planned receipt during the study period.\n12. Receipt of a live virus vaccine within 2 months prior to enrollment.\n13. Receipt of influenza vaccine within 15 days prior to enrollment, or planned receipt of influenza vaccine within 15 days post-enrollment, or planned receipt of influenza vaccine between Days 16-28 post-enrollment at an injection site different from the study vaccine cannot be ensured.\n14. Receipt of any other licensed vaccine (excluding live virus vaccines and influenza vaccine) within 1 month prior to enrollment, or planned receipt of any other licensed vaccine (excluding influenza vaccine) within 1 month post-enrollment.\n15. Acute illness or acute exacerbation of chronic disease within 3 days prior to enrollment, or known or suspected active infection.\n16. Fever (axillary temperature \\>37.0°C) on the day of scheduled study vaccination, or abnormal findings on physical examination that preclude vaccination.\n17. Skin lesions, inflammation, ulcers, rash, or scarring at the intended injection site that may interfere with vaccination or local reaction assessment.\n18. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical trial.","2 Years","6 Years",{"count":59,"type":22},660,[25],"The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years.\n\nThe main questions it aims to answer are:\n\nIs the immune response induced by the investigational vaccine non-inferior to that of the licensed control vaccine, as measured by serum antibody levels? What safety profile does the investigational vaccine have in this pediatric population? Researchers will compare the investigational vaccine group with the control group (licensed ACYW135 polysaccharide vaccine) to determine if the new vaccine provides comparable immune protection with an acceptable safety profile.\n\nParticipants will:\n\nReceive a single dose of either the investigational vaccine or the control vaccine by intramuscular injection; Provide two blood samples (before vaccination and 30 days after) for antibody testing; Have their vaccination site and overall health monitored for AE\u002FAR immediately after injection, for 7 days and for 30 days through diary card and follow-up contacts; Be followed for serious adverse events for 6 months after vaccination. A total of 660 participants will be enrolled and randomly assigned in a 1:1 ratio to either the investigational group or the control group.",[63,64],"Epidemic Meningitis","Meningococcal Vaccines","2026-03-29",{"date":67,"type":40},"2026-04-01",{"date":69,"type":22},"2026-03-22",{"date":71,"type":22},"2026-11",{"name":46,"class":47},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100631832","phase-3-phase--trial-of-group-acyw135-meningococcal-conjugate-vaccine-in-children-aged-3-5-months-100631832","NCT07505810","Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months","A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of the Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 3 to 5 Months","Inclusion Criteria:\n\n1. Healthy participants aged 3 to 5 months.\n2. The participant's legal guardian is capable of understanding and voluntarily signs the informed consent form.\n3. Willing and able to comply with all scheduled visits, sample collection, vaccination, and other trial procedures.\n4. Provision of legal identification documentation.\n\nExclusion Criteria:\n\n1. History (or suspected history) of meningococcal disease.\n2. History of infantile wheezing; history of allergy to the vaccine or any vaccine components (Group A\u002FC\u002FY\u002FW135 meningococcal capsular polysaccharide, mannitol, sucrose, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, water for injection), such as urticaria, dyspnea, angioedema; or other serious adverse reactions following prior vaccination.\n3. Prior vaccination with any meningococcal vaccine (including but not limited to: Group A meningococcal polysaccharide vaccine, Group A\u002FC meningococcal polysaccharide\u002Fconjugate vaccine, ACYW135 meningococcal polysaccharide\u002Fconjugate vaccine, etc.).\n4. Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to asplenia, functional asplenia, HIV infection in the participant or the participant's mother), current perianal abscess, or severe eczema.\n5. Coagulation disorders (e.g., coagulation factor deficiency, platelet abnormalities) or history of significant bleeding, hematoma, or ecchymosis following intramuscular injection or venipuncture.\n6. Presence of poorly controlled persistent disease conditions or history of serious illnesses, including but not limited to cardiovascular diseases, hematological diseases, hepatorenal diseases, gastrointestinal diseases, respiratory diseases, malignancies, or history of major organ transplantation.\n7. Severe congenital anomalies, genetic defects, or malnutrition.\n8. Newborn gestational age \\\u003C37 weeks or ≥42 weeks.\n9. Birth weight \\\u003C2500g or \\>4000g, or history of difficult birth, resuscitation at birth, or neurological damage.\n10. Presence of or history of severe neurological disorders \\[epilepsy, convulsions or seizures\\], or family history of psychiatric disorders.\n11. Receipt of immunoglobulins or other blood products within the past 3 months, or planned receipt of such treatments during the study period.\n12. Prior receipt of immunosuppressants or other immunomodulatory therapy for ≥14 days (e.g., prednisone ≥20 mg\u002Fday or ≥2 mg\u002Fkg\u002Fday, or equivalent), cytotoxic therapy, or planned receipt of such therapies during the study period.\n13. Receipt of any other investigational drug or vaccine within the past 3 months, or planned receipt during the study period.\n14. Receipt of a live attenuated vaccine within the past 14 days, or receipt of a subunit or inactivated vaccine within the past 7 days.\n15. Receipt of any other licensed vaccine within the past 28 days where administration at a different injection site from the study vaccine cannot be ensured.\n16. Acute illness or acute exacerbation of persistent disease conditions within the past 3 days, or known or suspected active infection.\n17. Fever (axillary temperature \\>37.0°C) on the day of scheduled study vaccination, or abnormal findings on physical examination that preclude vaccination.\n18. Skin lesions, inflammation, ulcers, rash, or scarring at the intended injection site that may interfere with vaccination or local reaction assessment.\n19. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical trial.","3 Months","5 Months",{"count":83,"type":22},880,[25],"The goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety of a booster dose administered at 12 months of age, in healthy children aged 3 to 5 months.\n\nThe main questions it aims to answer are:\n\nIs the immune response induced by the primary series of the investigational vaccine non-inferior to that of the licensed control vaccine? What is the safety profile of the investigational vaccine during the primary series and booster dose? Does the investigational vaccine provide immune persistence up to 12 months of age? What is the immunogenicity of a booster dose administered at 12 months of age? Researchers will compare the investigational vaccine group with the active comparator group (CanSinoBIO MCV-ACYW) during both the primary immunization phase and the booster phase.\n\nParticipants will:\n\nBe randomly assigned in a 1:1 ratio to receive either three doses of the investigational vaccine or three doses of the control vaccine according to a 0,1,2-month schedule during the primary immunization phase; Receive a booster dose at 12 months of age (either investigational vaccine or control vaccine according to group assignment); Provide blood samples at four time points: before primary vaccination, 30 days after primary vaccination, before booster vaccination (12 months of age), and 30 days after booster vaccination; Be observed for 30 minutes after each dose for immediate adverse reactions; Have solicited local and systemic adverse events recorded for 7 days after each dose using diary cards; Have unsolicited adverse events recorded for 30 days after each dose using diary cards; Be monitored for serious adverse events for at least 6 months after the last dose administered; A total of 880 participants will be enrolled.",[63,64],{"date":67,"type":40},{"date":69,"type":22},{"date":90,"type":22},"2028-01",{"name":46,"class":47},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":108,"locationsCount":4},"100631833","phase-3-phase--trial-of-group-acyw135-meningococcal-conjugate-vaccine-in-children-aged-6-11-months-100631833","NCT07505823","Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months","A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of the Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 6 to 11 Months","Inclusion Criteria:\n\n1. Healthy participants aged 6 to 11 months.\n2. The participant's legal guardian is capable of understanding and voluntarily signs the informed consent form.\n3. Willing and able to comply with all scheduled visits, sample collection, vaccination, and other trial procedures.\n4. Provision of legal identification documentation.\n\nExclusion Criteria:\n\n1. History (or suspected history) of meningococcal disease.\n2. History of infantile wheezing; history of allergy to the vaccine or any vaccine components (Group A\u002FC\u002FY\u002FW135 meningococcal capsular polysaccharide, mannitol, sucrose, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, water for injection), such as urticaria, dyspnea, angioedema; or other serious adverse reactions following prior vaccination.\n3. Prior vaccination with any meningococcal vaccine (including but not limited to: Group A\u002FC meningococcal polysaccharide\u002Fconjugate vaccine, ACYW135 meningococcal polysaccharide\u002Fconjugate vaccine, Group A meningococcal polysaccharide vaccine, etc.).\n4. Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to asplenia, functional asplenia, HIV infection in the participant or the participant's mother), or current perianal abscess.\n5. Coagulation disorders (e.g., coagulation factor deficiency, platelet abnormalities) or history of significant bleeding, hematoma, or ecchymosis following intramuscular injection or venipuncture.\n6. Presence of poorly controlled chronic diseases or history of serious illnesses, including but not limited to cardiovascular diseases, hematological diseases, hepatorenal diseases, gastrointestinal diseases, respiratory diseases, malignancies, or history of major organ transplantation.\n7. Severe congenital anomalies, genetic defects, or malnutrition.\n8. Presence of or history of severe neurological disorders \\[epilepsy, convulsions or seizures\\], or family history of psychiatric disorders.\n9. Receipt of immunoglobulins or other blood products within the past 3 months, or planned receipt of such treatments during the study period.\n10. Receipt of immunosuppressants or other immunomodulatory therapy for ≥14 days (e.g., prednisone ≥20 mg\u002Fday or ≥2 mg\u002Fkg\u002Fday, or equivalent), cytotoxic therapy within the past 6 months, or planned receipt of such therapies during the study period.\n11. Receipt of any other investigational drug or vaccine within the past 3 months, or planned receipt during the study period.\n12. Receipt of a live attenuated vaccine within the past 14 days, or receipt of a subunit or inactivated vaccine within the past 7 days.\n13. Receipt of any other licensed vaccine within the past 28 days where administration at a different injection site from the study vaccine cannot be ensured.\n14. Acute illness or acute exacerbation of chronic disease within the past 3 days, or known or suspected active infection.\n15. Fever (axillary temperature \\>37.0°C) on the day of scheduled study vaccination, or abnormal findings on physical examination that preclude vaccination.\n16. Skin lesions, inflammation, ulcers, rash, or scarring at the intended injection site that may interfere with vaccination or local reaction assessment.\n17. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical trial.","11 Months",{"count":101,"type":22},1040,[25],"The goal of this clinical trial is to evaluate the immunogenicity, safety, and persistence of the immune response of a group ACYW135 meningococcal conjugate vaccine in healthy children aged 6 to 11 months.\n\nThe main questions it aims to answer are:\n\nIs the immune response induced by the investigational vaccine non-inferior to that of the licensed control vaccine following the primary series? What is the safety profile of the investigational vaccine during the primary series and booster dose? Does the investigational vaccine provide durable immune persistence up to 18 months of age? What is the immunogenicity of a booster dose administered at 18 months of age? Researchers will compare the investigational vaccine group with the active comparator group (licensed group ACYW135 meningococcal conjugate vaccine (CRM197 carrier), CanSinoBIO) during the primary immunization phase. Only the investigational group will receive a booster dose at 18 months of age to evaluate booster immunogenicity and safety.\n\nParticipants will:\n\nBe randomly assigned in a 1:1 ratio to receive either two doses of the investigational vaccine or two doses of the control vaccine according to a 0,1-month schedule during the primary immunization phase; In the investigational group only, receive a booster dose at 18 months of age; Provide blood samples at three time points: before primary vaccination, 30 days after primary vaccination, and at 18 months of age to assess primary immunogenicity and immune persistence; In the investigational group only, provide an additional blood sample 30 days after the booster dose to assess booster immunogenicity; Be observed for 30 minutes after each dose for immediate adverse reactions; Have solicited local and systemic adverse events recorded for 7 days after each dose using diary cards; Have unsolicited adverse events recorded for 30 days after each dose using diary cards; Be monitored for serious adverse events for at least 6 months after the last dose administered; A total of 1040 participants will be enrolled.",[63,64],{"date":67,"type":40},{"date":69,"type":22},{"date":90,"type":22},{"name":46,"class":47},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":16,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100631834","phase-3-phase--trial-of-group-acyw135-meningococcal-conjugate-vaccine-in-children-aged-12-23-months-100631834","NCT07505836","Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months","A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of the Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 12 to 23 Months","Inclusion Criteria:\n\n1. Healthy participants aged 12 to 23 months.\n2. The participant's legal guardian is capable of understanding and voluntarily signs the informed consent form.\n3. Willing and able to comply with all scheduled visits, sample collection, vaccination, and other trial procedures.\n4. Provision of legal identification documentation.\n\nExclusion Criteria:\n\n1. History (or suspected history) of meningococcal disease.\n2. History of infantile wheezing; history of allergy to the vaccine or any vaccine components (Group A\u002FC\u002FY\u002FW135 meningococcal capsular polysaccharide, mannitol, sucrose, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, water for injection), such as urticaria, dyspnea, angioedema; or other serious adverse reactions following prior vaccination.\n3. Prior vaccination with Group A meningococcal polysaccharide vaccine with an interval ≤6 months since the most recent dose; prior vaccination with any other meningococcal vaccine other than Group A meningococcal polysaccharide vaccine (including but not limited to: Group A\u002FC meningococcal polysaccharide\u002Fconjugate vaccine, ACYW135 meningococcal polysaccharide\u002Fconjugate vaccine).\n4. Presence of autoimmune diseases or immunodeficiency diseases (including but not limited to asplenia, functional asplenia, HIV infection in the participant or the participant's mother).\n5. Coagulation disorders (e.g., coagulation factor deficiency, platelet abnormalities) or history of significant bleeding, hematoma, or ecchymosis following intramuscular injection or venipuncture.\n6. Presence of poorly controlled chronic diseases or history of serious illnesses, including but not limited to cardiovascular diseases, metabolic diseases, hematological diseases, hepatorenal diseases, gastrointestinal diseases, respiratory diseases, malignancies, or history of major organ transplantation.\n7. Severe congenital anomalies, genetic defects, or malnutrition.\n8. Presence of or history of severe neurological disorders \\[epilepsy, convulsions or seizures\\], or family history of psychiatric disorders.\n9. Receipt of immunoglobulins or other blood products within the past 3 months, or planned receipt of such treatments during the study period.\n10. Receipt of immunosuppressants or other immunomodulatory therapy for ≥14 days (e.g., prednisone ≥20 mg\u002Fday or ≥2 mg\u002Fkg\u002Fday, or equivalent), cytotoxic therapy within the past 6 months, or planned receipt of such therapies during the study period.\n11. Receipt of any other investigational drug or vaccine within the past 3 months, or planned receipt during the study period.\n12. Receipt of a live attenuated vaccine within the past 14 days, or receipt of a subunit or inactivated vaccine within the past 7 days.\n13. Receipt of any other licensed vaccine within the past 28 days where administration at a different injection site from the study vaccine cannot be ensured.\n14. Acute illness or acute exacerbation of chronic disease within the past 3 days, or known or suspected active infection.\n15. Fever (axillary temperature \\>37.0°C) on the day of scheduled study vaccination, or abnormal findings on physical examination that preclude vaccination.\n16. Skin lesions, inflammation, ulcers, rash, or scarring at the intended injection site that may interfere with vaccination or local reaction assessment.\n17. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical trial.","12 Months","23 Months",{"count":101,"type":22},[25],"The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 Meningococcal conjugate vaccine in healthy children aged 12 to 23 months.\n\nThe main questions it aims to answer are:\n\nIs the immune response induced by the investigational vaccine non-inferior to that of the licensed control vaccine? What safety profile does the investigational vaccine have in this pediatric population? Researchers will compare the investigational vaccine group with the active comparator group (licensed ACYW135 meningococcal conjugate vaccine (CRM197 carrier), CanSinoBIO; hereinafter referred to as CanSinoBIO MCV-ACYW) to determine if the new vaccine provides comparable immune protection with an acceptable safety profile.\n\nParticipants will:\n\nReceive two doses of either the investigational vaccine or the control vaccine according to a 0,1-month schedule; Be observed for 30 minutes after each dose for immediate adverse reactions; Have solicited local and systemic adverse events recorded for 7 days after each dose using diary cards; Have unsolicited adverse events recorded for 30 days after each dose using diary cards; Be monitored for serious adverse events for at least 6 months after completion of the primary immunization series; A total of 1040 participants will be enrolled and randomly assigned in a 1:1 ratio to either the investigational group or the control group.",[63,64],{"date":67,"type":40},{"date":69,"type":22},{"date":125,"type":22},"2027-01",{"name":46,"class":47},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100628086","phase-4-phase-iv-clinical-study-of-sequential-vaccination-of-sabin-strain-and-wild-strain-inactivated-poliovirus-vaccine-100628086","NCT07457060","Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","An Open-labelled, Randomized, Controlled, Clinical Trial to Evaluate the Immunogenicity and Tolerability of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","Inclusion Criteria:\n\n1. Infants of 2 months old (aged 56-84 days).\n2. Have a parent\u002Flegal guardian who has provided written informed consent after being fully informed about the study.\n3. Be able to provide the vaccination records since birth.\n4. The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C during or before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).\n\nExclusion Criteria:\n\n1. History of any polio vaccination.\n2. History of severe allergic reaction to previous vaccinations or hypersensitivity to any vaccine component.\n3. Premature infants (born before week 37 of gestation).\n4. History of asphyxia rescue or nervous system injury.\n5. Congenital malformations, developmental disorders, clinically significant genetic defects, severe malnutrition.\n6. Autoimmune diseases or immunodeficiency\u002Fimmunosuppression.\n7. Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders.\n8. Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders).\n9. Received immunosuppressant (excluding topical or inhaled corticosteroids), cytotoxic drug, or other immunomodulatory therapies.\n10. Received blood products before trial vaccine inoculation.\n11. Received other study drugs within 30 days before enrollment.\n12. Received live attenuated vaccines within 14 days before enrollment.\n13. Received subunit or inactivated vaccines within 7 days before enrollment.\n14. Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment.\n15. Significant acute diseases, chronic infections, or axillary temperature ≥ 37.5°C before enrollment.\n16. Any other factors deemed by the investigators as unsuitable for participation.","56 Days","84 Days",{"count":137,"type":22},480,[139],"PHASE4","The goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes",[142],"Poliomyelitis","RECRUITING","2026-03-03",{"date":146,"type":40},"2026-03-09",{"date":148,"type":40},"2025-11-27",{"date":150,"type":22},"2026-10-19",{"name":46,"class":47},3,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":16,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100625099","phase-1-study-to-evaluate-the-safety-of-a-lyophilized-rsv-mrna-vaccine-100625099","NCT07418229","Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine","A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety of Different Doses of a Lyophilized RSV mRNA Vaccine in Adults Aged 18 Years and Older","Inclusion Criteria:\n\n1. Participants can understand and voluntarily sign the informed consent form;\n2. Able to provide legal identity documents;\n3. Healthy individuals aged 18 years and above;\n4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures (such as correct use of condoms, or female participants using combined oral contraceptives, intrauterine devices) from the time the participant signs the informed consent form until 6 months after the administration of the investigational vaccine, and have no plans to donate sperm or ovums; Female participants of childbearing potential must also have adopted effective contraceptive measures within 2 weeks before enrollment.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from this trial:\n\n1. Those with fever on the day of vaccination with the trial vaccine, with an axillary temperature \\> 37.0℃ before vaccination;\n2. Those with a history of previous RSV vaccination, or a history of RSV infection within 6 months before enrollment.\n3. Known to be allergic to vaccines or vaccine components;\n4. Before vaccination, the electrocardiogram examination and clinical laboratory test indicators specified in the protocol are abnormal and clinically significant;\n5. Female participants who are breastfeeding or pregnant;\n6. Having autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, splenectomy, HIV infection);\n7. History of poorly controlled chronic diseases or severe diseases, including but not limited to cardiovascular diseases (such as hypertension uncontrolled by drugs, i.e., systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg for participants aged 18-59 years old, systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg for participants aged 60 years old and above, as well as congenital heart disease, atrial fibrillation, myocarditis, pericarditis), hematological system diseases, liver and kidney diseases, respiratory system diseases, malignant tumors, history of transplantation of major functional organs, or any other diseases or physiological conditions that the researcher believes can interfere with the trial results;\n8. Current encephalopathy (such as damage to cerebral nerve tissue caused by congenital hypoplasia of the brain, brain trauma, brain tumors, cerebral hemorrhage, brain infection, chemical drug poisoning, etc.);\n9. Severe neurological diseases, such as a history of demyelinating diseases including but not limited to Guillain-Barré syndrome, multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis, etc., or a history of convulsions, epilepsy, or a family history of mental illness;\n10. Having a doctor-diagnosed coagulation dysfunction (such as coagulation factor deficiency, coagulative diseases, abnormal platelets);\n11. Having received systemic immunosuppressive agents or other immunomodulatory treatments (prednisone \\[≥ 20 mg\u002Fday\\] or its equivalent) for ≥ 14 days within the past 3 months, cytotoxic therapy, or planning to receive such treatments during the study period;\n12. Having received immunoglobulin or other blood products within 3 months before receiving the trial vaccine, or planning to receive such treatments during the study period;\n13. Currently participating in other clinical trials, or planning to receive such drugs or vaccines during the study period;\n14. Having received live attenuated vaccines within the past 14 days or other vaccines with processes such as subunit or inactivated vaccines within 7 days;\n15. Having various acute diseases or acute exacerbation of chronic diseases within the past 7 days, or known or suspected active infection;\n16. Axillary temperature \\> 37.0℃ within the past 3 days, or use of anti-allergic drugs, non-steroidal antipyretic analgesics, etc.;\n17. Those with skin damage, inflammation, ulceration, rash, scarring, or other conditions at the target vaccination site that may interfere with vaccination or observation of local reactions;\n18. According to the researcher's judgment, participants have any other factors that make them unsuitable for participating in the clinical trial.","18 Years",{"count":162,"type":22},60,[164],"PHASE1","To evaluate the safety of Sinovac RSV mRNA among participants aged ≥18 years",[167,168],"RSV","mRNA Vaccine",[170],"RSV vaccine","2026-02-11",{"date":173,"type":40},"2026-02-18",{"date":146,"type":22},{"date":176,"type":22},"2027-05-30",{"name":46,"class":47},1,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":16,"sex":17,"minAge":160,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100624936","phase-3-phase-iiib-clinical-trial-to-evaluate-lot-to-lot-consistency-of-sinovac-rabies-vaccine-100624936","NCT07416110","Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine","Lot-to-lot Consistency and Safety of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried in Healthy Individuals Aged 18-45 Years: A Randomized, Double-Blind Phase IIIb Clinical Trial","Inclusion Criteria:\n\n1. Participants are able to understand and voluntarily sign the Informed Consent Form;\n2. Able to provide legal identity documents;\n3. Age 18 to 45 years;\n4. Stable health status (defined as stable underlying disease status within 3 months prior to enrollment, i.e., no change in original treatment or hospitalization due to disorder aggravation);\n5. Female participants of childbearing potential must voluntarily adopt effective contraception measures from the signing of the Informed Consent Form until 2 months after the last dose of the investigational Vaccine in the primary immunization series, and have no plans to donate eggs; male participants have no plans to donate sperm; female participants of childbearing potential must also have adopted effective contraception measures within 2 weeks prior to Enrollment.\n\nExclusion Criteria:\n\n1. For subjects with pyrexia on the scheduled vaccination day, axillary temperature \\>37.3℃ before vaccination;\n2. Previous use of anti-Rabies Passive immunization preparations (including but not limited to equine-derived Immunoglobulin ERIG, human-derived Immunoglobulins HRIG, and rabies monoclonal antibody preparations, etc.) or previous Vaccination with human Rabies Vaccine;\n3. Individuals with mammalian animal bites\u002Fscratches (e.g., dog\u002Fcat) and broken skin (i.e., Category II or higher exposure) within the past year.;\n4. Female participants who are lactating or pregnant (including those with a positive urine pregnancy test).\n5. Known allergy to any component of the trial Vaccine, or a history of severe allergies (such as anaphylactic shock, allergic laryngeal edema, allergic purpura, severe urticarial rash, dyspnea, angioneurotic edema, etc.);\n6. Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, asplenia, functional asplenia, splenectomy);\n7. Poorly controlled chronic diseases or history of severe diseases, including but not limited to cardiovascular disorders (e.g., uncontrolled hypertension: systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg), metabolic diseases (e.g., poorly controlled diabetes), hematological diseases, liver and kidney diseases, digestive system diseases, respiratory system disorders, history of major organ transplantation, malignant neoplasms within the past five years, or any other diseases or physiological conditions that the investigator believes may interfere with the trial results.\n8. History of encephalopathy with significant recovered with sequelae or dysfunction, or current encephalopathy (e.g., congenital cerebral dysgenesis, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarct, brain infection, chemical drug poisoning, etc., causing brain nerve tissue injury); history of convulsions, epilepsy, mental illness or family history of mental illness, or other serious neurological diseases;\n9. Presence of physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiency, coagulation disorders, platelet abnormalities);\n10. Systemic immunosuppressive agents or other immunomodulatory therapy for ≥14 days within the past 6 months (prednisone ≥20 mg\u002Fday or ≥2 mg\u002F(kg·day), or equivalent), cytotoxic therapy, or planned receipt of such therapy during the study period;\n11. Received Immunoglobulins or other blood products within 3 months prior to receiving the investigational Vaccine, or plans to receive such treatment during the study period;\n12. Received other Study Drug or Vaccine within the past 30 days, or plans to receive such drug or Vaccine during the study period;\n13. Within 14 days prior to receiving the investigational vaccine, vaccination with a live attenuated vaccine, or within 7 days, vaccination with subunit, inactivated, or other types of vaccines.\n14. Currently participating in other Vaccine or drug Clinical Studies, or planning to participate in other Clinical Trials during the study period;\n15. Subjects with skin injuries, inflammation, ulcers, skin rash, or scars at the Vaccination site that may interfere with dosing or the observation of local reactions.\n16. Within 3 days prior to vaccination, any acute disease or acute exacerbation of a chronic disease, or known or suspected active infection;\n17. Based on the Investigator's judgment, the participant has any other discomfort or factors suitable for participating in the clinical trial.","45 Years",{"count":188,"type":22},912,[25],"To evaluate immunogenicity consistency between three consecutive batches of commercial-scale productions for Sinovac Rabies vaccine",[192],"Rabies (Healthy Volunteers)",[194,195,196],"rabies vaccine","serum-free","lot-to-lot consistency","2026-02-10",{"date":199,"type":40},"2026-02-17",{"date":201,"type":22},"2026-03-04",{"date":203,"type":22},"2027-06-30",{"name":46,"class":47},2,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":16,"sex":17,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":178},"100623697","phase-1-study-to-evaluate-the-safety-and-immunogenicity-of-a-lyophilized-herpes-zoster-virus-mrna-vaccine-100623697","NCT07400003","Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","A Randomized, Double-Blind, Controlled Phase I\u002FII Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of a Lyophilized Herpes Zoster Virus mRNA Vaccine in Adults Aged 40 Years and Older","Inclusion Criteria:\n\n* Phase I: Age ≥ 40 years; Phase II: Age ≥ 50 years;\n* Participants are able to understand and voluntarily sign the informed consent form;\n* Able to provide legal identification;\n* Participants of childbearing potential and their sexual partners agree to voluntarily adopt effective contraceptive measures from the signing of the informed consent form until 6 months after the last dose of the investigational vaccine, with no plans for sperm or egg donation;\n* Agree to comply with the visit schedule, sample collection, vaccination, and other trial procedures throughout the study period, and remain accessible at all times during the trial.\n\nExclusion Criteria:\n\n* History of chickenpox or herpes zoster in adulthood;\n* History of chickenpox or herpes zoster vaccination (including administration of registered products or participation in clinical trials of chickenpox or herpes zoster vaccines);\n* Close contact with patients infected with chickenpox or herpes zoster within the past 30 days;\n* Clinically significant abnormalities in protocol-specified clinical laboratory tests prior to vaccination (applicable to Phase I clinical trials only):\n\nA. Hematological parameters: White blood cell count (WBC), hemoglobin (Hb), platelet count (Plt); B. Blood biochemical parameters: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), fasting blood glucose (Glu), creatinine (CR); C. Urinalysis parameter: Urine protein (PRO); D. Coagulation parameters: Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), international normalized ratio (INR); E. 12-lead electrocardiogram (ECG).\n\n* Poorly controlled chronic diseases or significant medical history, including but not limited to cardiovascular diseases (e.g., poorly controlled hypertension defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg for participants aged 40-59 years prior to enrollment, or systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg for participants aged ≥60 years), metabolic disorders (e.g., poorly controlled diabetes), hematological diseases, hepatic or renal diseases, digestive system diseases, respiratory system diseases, history of major organ transplantation, or malignancy within the past five years;\n* History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that increases the risk of myocarditis or pericarditis;\n* Autoimmune diseases, immunodeficiency diseases, or family history thereof (including but not limited to psoriasis, systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, acute disseminated encephalomyelitis, facial paralysis, hypersensitivity reactions, polymyalgia rheumatica, rheumatoid arthritis, Guillain-Barré syndrome, asplenia, functional asplenia, HIV infection);\n* Coagulation disorders (e.g., coagulation factor deficiencies, platelet abnormalities, or other coagulopathies);\n* Current or previous severe neurological disorders (epilepsy, convulsions, or seizures) or psychiatric illnesses, or family history of psychiatric disorders;\n* Acute illnesses or acute exacerbations of chronic diseases within the past 7 days, or known or suspected active infections;\n* Immunosuppressive therapy or other immunomodulatory treatments (prednisone ≥20 mg\u002Fday or equivalent for \\>14 days), cytotoxic therapy within the past 6 months, or planned use during the trial;\n* Administration of immunoglobulins or other blood products within the past 3 months (use of hepatitis B immunoglobulin within the past 1 month), or planned use during the trial;\n* Participation in other clinical studies within the past 30 days or planned participation during this trial;\n* Vaccination with live-attenuated vaccines or nucleic acid vaccines within the past 28 days, or vaccination with subunit, inactivated, or other types of vaccines within the past 14 days;\n* Known allergy to vaccines or vaccine components, such as urticaria, dyspnea, or angioedema following vaccination;\n* Pregnancy, lactation, or positive urine pregnancy test in female participants;\n* Fever (axillary temperature ≥37.3°C) within 3 days prior to vaccination or use of antipyretics, analgesics, or antihistamines (e.g., acetaminophen, ibuprofen, loratadine, cetirizine, etc.) as reported during inquiry;\n* Physical examination deemed unsatisfactory on the day of planned vaccination;\n* Skin lesions, inflammation, ulcers, rashes, scars, or other conditions at the target injection site that may interfere with administration or local reaction assessment;\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial.","40 Years",{"count":215,"type":22},519,[164,217],"PHASE2","This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.",[220,168],"Herpes Zoster","2026-02-02",{"date":197,"type":40},{"date":224,"type":40},"2026-01-06",{"date":226,"type":22},"2027-04-30",{"name":46,"class":47},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":16,"sex":235,"minAge":160,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":205},"100609176","phase-3-influenza-vaccine-split-virion-inactivated-quadrivalent-in-pregnant-women-100609176","NCT07211152","Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","A Phase Ⅲ, Randomized, Double-blind, Positive Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of an Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","Inclusion Criteria:\n\n1. Pregnant women aged 18 to 39 years in good health or medically stable.\n2. Gestational age of 20 to 32 weeks, based on last menstrual period, early or late ultrasound dating.\n3. The participant was tested negative for HIV, Syphilis, Hepatitis B, Hepatitis C infection according to medical records or rapid tests.\n4. Participants should provide verifiable identification.\n5. Participants are able to understand and sign the informed consent form voluntarily;\n6. Participants are willing and able to adhere to visit schedules and all study requirements.\n\nExclusion Criteria:\n\n1. Receipt of any seasonal influenza vaccine within 6 months prior to enrollment, or plans to receive other influenza vaccines during the study;\n2. Participants with previous or concurrent dangerous pregnancy complications such as gestational diabetes mellitus (GDM), pregnant induced hypertension, preeclampsia and known uterine anomaly;\n3. History of preterm delivery, or spontaneous abortion;\n4. Known fetal congenital anomaly, e.g. genetic abnormality or major congenital malformation based on antenatal ultrasound;\n5. Signs or symptoms of active preterm labor, defined as regular uterine contractions with cervical change (dilation\u002Feffacement);\n6. History of Guillain-Barré syndrome within 6 weeks of a prior dose of any influenza vaccine;\n7. Received any vaccine in the 4 weeks prior to study vaccination, or plans to receive any vaccine within 4 weeks after study vaccination;\n8. Serious allergic reaction or other serious adverse reaction to any influenza vaccines or their components;\n9. Autoimmune diseases, immunodeficiency, any immunosuppressant within 6 months prior to vaccination (≥ 20mg\u002Fday prednisone or equivalent, but corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis are permitted) or cytotoxic therapy, or plans for such treatment during the study;\n10. Diagnosed abnormal coagulation function (e.g., coagulation factor deficiency, coagulation disorders, or platelet abnormalities), or obvious bruising following venipuncture;\n11. Significant chronic diseases that, in the judgement of the investigator, might interfere with the study (may include, but are not limited to cardiovascular disease, liver or kidney disorders, HIV infection or malignant tumor);\n12. Current or history of severe neurological diseases (such as epilepsy, convulsions or seizures) or psychiatric disorders, or family history of psychiatric disorders;\n13. Acute diseases or acute stage of chronic diseases within 7 days prior to vaccination;\n14. Receipt of blood, blood-derived products or immunoglobulins within 3 months prior to vaccination or plans for such treatment in the study;\n15. Alcoholism or history of drug abuse;\n16. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to enrollment, or plan to receive investigational drugs\u002Fvaccines during the study period;\n17. Fever on vaccination day, with axillary temperature ≥ 37.3°C pre-vaccination;\n18. Any other factors which are unsuitable for participation in the clinical trial as judged by the investigator.","FEMALE","39 Years",{"count":238,"type":22},150,[25],"This is a randomized, double-blind, positive controlled phase Ⅲ clinical trial to assess the immunogenicity and safety of Sinovac QIV in pregnant women. A total of 150 healthy pregnant women aged 18\\~39 years at 20 to 32 weeks of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac QIV or Vaxigrip QIV, respectively.\n\nBlood samples will be collected from participants prior to vaccination and 28 days after vaccination. Moreover, to evaluate trans-placental antibodies, blood samples at the end of the gestation period (delivery) and the cord blood sample will be collected, if applicable.\n\nFor safety assessment, any immediate adverse events within 30 minutes, solicited local and systemic adverse events within 7 days and unsolicited adverse events within 28 days will be collected. Serious adverse events will be collected within 8 weeks after delivery. Pregnancy and birth outcomes will be collected as well.",[242],"Influenza",[244],"pregnant women","2026-01-26",{"date":247,"type":40},"2026-01-28",{"date":249,"type":40},"2025-10-13",{"date":251,"type":22},"2026-06",{"name":46,"class":47},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":152},"100620180","phase-4-phase-iv-clinical-study-of-sipv-administration-in-adolescent-and-adult-populations-100620180","NCT07354269","Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","Phase IV Clinical Study Comparing the Immunogenicity and Safety of a Single-dose Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains (sIPV) in Adolescents and Adults Aged 7-50 Years Versus the Primary Immunization With DTaP-IPV-Hib Pentavalent Vaccine in Infants Aged 3 Months","Inclusion Criteria:\n\n1. Healthy adolescents and adults aged 7-50 years, and healthy infants aged 3 months;\n2. Participants and\u002For their guardians are able to understand and voluntarily sign the informed consent form (for participants aged 7-17 years, both the participant and their guardian need to sign);\n3. Provide valid proof of identity;\n4. Willing and able to comply with all visit schedules, sample collections, vaccinations, and other study procedures, and remain contactable throughout the study period;\n5. Fertile participants and their sexual partners voluntarily adopt effective contraceptive measures from the signing of the informed consent form until 3 months after vaccination with the study vaccine, and have no plans to donate sperm or eggs.\n\nExclusion Criteria:\n\n1. Known history of polio\u002Fpolio infection.\n2. Exposure or suspected exposure to pertussis, diphtheria, and tetanus within the past 30 days, such as having a confirmed case of pertussis or diphtheria in the household (applies to infants aged 3 months).\n3. History of uncontrolled chronic or severe illnesses, including but not limited to cardiovascular disease, hematological disorders, liver and kidney diseases, digestive system diseases, respiratory diseases, malignant tumors, and history of major organ transplantation.\n4. Presence of autoimmune diseases, immunodeficiency disorders (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection).\n5. Abnormal coagulation function (such as coagulation factor deficiency, platelet abnormalities).\n6. Premature birth (delivery before the 37th week of gestation) or low birth weight (birth weight \\\u003C2500g), or history of asphyxiation, or history of neurological damage (applies to infants aged 3 months).\n7. Severe congenital malformations, genetic defects, and malnutrition.\n8. Current or past history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding a history of febrile seizures\\]) or psychiatric disorders, or family history of psychiatric disorders.\n9. Acute exacerbations of various acute or chronic diseases within the past 3 days, or known or suspected active infections.\n10. History of vaccination with any vaccine containing DTP, IPV, Hib components, or pneumococcal polysaccharide conjugate vaccine (applies to infants aged 3 months).\n11. Received immunosuppressive or other immunomodulatory treatment for ≥14 days within the past 6 months (≥20mg\u002Fday of prednisone for those ≥18 years old, ≥2mg\u002Fkg\u002Fday for those \\\u003C18 years old, or equivalent doses), cytotoxic treatment, or plans to receive such treatment during the study.\n12. Received immunoglobulin or other blood products within the past 6 months, or plans to receive such treatment during the study.\n13. Received other investigational drugs or vaccines within the past 30 days, or plans to receive such drugs or vaccines during the study.\n14. Received live attenuated vaccines, nucleic acid vaccines within the past 14 days, or subunit or inactivated vaccines within the past 7 days.\n15. Known allergy to any component of the study vaccine (inactivated poliovirus, 199 medium, glycine, sodium chloride, potassium chloride, calcium chloride, magnesium phosphate, disodium phosphate, monosodium phosphate \\[for adolescents and adults\\]; inactivated poliovirus, diphtheria toxoid, tetanus toxoid, pertussis toxoid, pertussis filamentous hemagglutinin, Haemophilus influenzae type b capsular polysaccharide, tetanus protein conjugate \\[for infants aged 3 months\\]).\n16. Breastfeeding, pregnant, or planning to become pregnant within 3 months after vaccination in this study (applies only to adolescents and adults).\n17. Axillary temperature \\>37.0°C before vaccination on the day of the planned vaccination with the study vaccine.\n18. Unqualified physical examination results on the day of the planned vaccination with the study vaccine.\n19. Skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with vaccination or observation of local reactions.\n20. Any other factors deemed unsuitable for participation in the clinical study by the investigator.","50 Years",{"count":262,"type":22},180,[139],"The goal of this clinical study is to compare the immunogenicity and safety of one dose of sIPV in adolescents or adults aged 7-50 years with that of three doses of DTaP-IPV-Hib Pentavalent Vaccine in Infants Aged 3 Months",[142],"2026-01-14",{"date":268,"type":40},"2026-01-21",{"date":270,"type":40},"2025-09-26",{"date":272,"type":22},"2026-05-02",{"name":46,"class":47},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":16,"sex":17,"minAge":281,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":178},"100597192","phase-3-immunogenicity-and-safety-of-rabies-vaccine-serum-free-vero-cell-in-a-pre-exposure-prophylaxis-regimen-100597192","NCT07055295","Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen","Immunogenicity and Safety of a Rabies Vaccine (Serum-free Vero Cell), Freeze-dried in Comparison With Verorab®, in a Pre-exposure Prophylaxis Regimen in Healthy Populations Aged ≥1 Years: A Randomized, Double-Blind, Active-controlled Phase Ⅲ Clinical Trial","Inclusion Criteria:\n\n1. Populations aged ≥1 years old;\n2. Participants and\u002For participants' parents\u002Flegal guardians are able to understand and sign the informed consent form (ICF) voluntarily;\n3. Participants are able to comply with the study procedures based on the investigator's assessment;\n4. In a stable health status (defined as a stable preexisting disease status during the past 3 months, i.e., no change in treatment or hospitalization due to exacerbation of preexisting diseases);\n5. Participants were tested negative for HIV, Syphilis, Hepatitis B, Hepatitis C infection at the screening of this study (the test result should be provided)\n6. Female participants aged ≥15 years old with childbearing potential were tested negative for urine pregnancy test pre-vaccination, and also need to have effective contraceptive measures in the previous 2 weeks pre-vaccination;\n7. Participants of childbearing potential and their partners are willing to take effective contraceptive measures and have no sperm or ovum donation plan from the time of signing ICF to 28 days after the last dose of vaccination;\n8. Participants should provide verifiable identifications, and contact or be contacted with the investigators during the study period\n\nExclusion Criteria:\n\n1. Fever on vaccination day, with axillary temperature \\>37.0°C (aged ≥5years old) or \\>37.3°C (aged 1\\~4 years old) pre-vaccination;\n2. Previous vaccination against rabies (in pre- or post-exposure regimen) with either trial vaccines or licensed vaccines;\n3. Previous administration with rabies immunoglobulins or monoclonal antibodies;\n4. Bite by, or exposure to a potentially rabid animal in the previous 12 months with category Ⅱ or Ⅲ exposures;\n5. Female participants who are currently lactating or pregnant;\n6. Known serious allergy to vaccines or vaccine ingredients, such as severe urticaria, anaphylactic shock, allergic laryngeal edema, allergic purpura, or known other serious adverse reactions to vaccine;\n7. With severe congenital malformations or developmental disorders, genetic defects, severe malnutrition;\n8. With autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n9. With poor controlled chronic illnesses or history of severe diseases, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, a history of major organ transplantation, drug-uncontrolled hypertension (only for participants aged ≥18 years old: with systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg), or any other disease or medical condition that the investigator believes could interfere with the trial results;\n10. With current or past history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding history of febrile seizures\\]) or psychiatric disorders, or presence of a family history of psychiatric disorders;\n11. With coagulation disorders (eg. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;\n12. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment in this study;\n13. With long-term alcohol abuse \\[\\>14 drinks per week (1 drink =14 g 100% alcohol =360 mL beer, or 150 mL wine, or 45 mL distilled liquor\u002Fliquor)\\] or substance abuse (repeated and heavy use of narcotic drugs, psychotropic drugs, volatile organic solvents, etc.)\n14. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the study;\n15. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;\n16. Currently participating in other vaccine or drug clinical trials, or plan to participate in other clinical trials during the study;\n17. Receipt of live-attenuated vaccines within 14 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;\n18. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended vaccination site that may interfere with drug administration or observation of local reactions;\n19. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;\n20. Any other factors considered by the investigator to make the participant unsuitable for participation in the study","1 Year",{"count":283,"type":22},390,[25],"To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after pre-exposure prophylaxis (PrEP) vaccination, and to confirm its satisfying safety profile in the pediatric and adult population in a PrEP schedule",[287],"Rabies",[194,289,290],"Serum-free","pre-exposure prophylaxis","2025-06-27",{"date":293,"type":40},"2025-07-08",{"date":295,"type":22},"2026-03-01",{"date":297,"type":22},"2026-12-30",{"name":46,"class":47},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":16,"sex":17,"minAge":160,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":178},"100597237","phase-2-immunogenicity-and-safety-of-different-dosages-of-rabies-vaccine-serum-free-vero-cell-100597237","NCT07055880","Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)","Immunogenicity and Safety of Two Dosages of Rabies Vaccine (Serum-free Vero Cell), Freeze-dried in Comparison With Verorab®, in a Simulated Post-exposure Prophylaxis Regimen in Healthy Adults: A Randomized, Double-Blind, Active-controlled Phase Ⅱ Clinical Trial","Inclusion Criteria:\n\n1. Populations aged 18\\~59 years old;\n2. Participants are able to understand and sign the informed consent form (ICF) voluntarily;\n3. Participants are able to comply with the study procedures based on the investigator's assessment;\n4. In a stable health status (defined as a stable preexisting disease status during the past 3 months, i.e., no change in treatment or hospitalization due to exacerbation of preexisting diseases);\n5. Participant was tested negative for HIV, Syphilis, Hepatitis B, Hepatitis C infection at the screening of this study (the test result should be provided);\n6. Female participants of childbearing potential were tested negative for urine pregnancy test pre-vaccination, and also need to have effective contraceptive measures in the previous 2 weeks pre-vaccination;\n7. Participants of childbearing potential and their partners are willing to take effective contraceptive measures and have no sperm or ovum donation plan from the time of signing ICF to 28 days after the last dose of vaccination;\n8. Participants should provide verifiable identifications, and contact or be contacted with the investigators during the study period.\n\nExclusion Criteria:\n\n1. Fever on vaccination day, with axillary temperature \\>37.0°C pre-vaccination;\n2. Previous vaccination against rabies (in pre- or post-exposure regimen) with either trial vaccines or licensed vaccines;\n3. Previous administration with rabies immunoglobulins or monoclonal antibodies;\n4. Bite by, or exposure to a potentially rabid animal in the previous 12 months with category Ⅱ or Ⅲ exposures;\n5. Female participants who are currently lactating or pregnant;\n6. Known serious allergy to vaccines or vaccine ingredients, such as severe urticaria, anaphylactic shock, allergic laryngeal edema, allergic purpura, or known other serious adverse reactions to vaccine;\n7. With severe congenital malformations or developmental disorders, genetic defects, severe malnutrition;\n8. With autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n9. With poor controlled chronic illnesses or history of severe diseases, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, a history of major organ transplantation, drug-uncontrolled hypertension (with systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg), or any other disease or medical condition that the investigator believes could interfere with the trial results;\n10. With current or past history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding history of febrile seizures\\]) or psychiatric disorders, or presence of a family history of psychiatric disorders;\n11. With coagulation disorders (eg. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;\n12. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment in this study;\n13. With long-term alcohol abuse \\[\\>14 drinks per week (1 drink =14 g 100% alcohol =360 mL beer, or 150 mL wine, or 45 mL distilled liquor\u002Fliquor)\\] or substance abuse (repeated and heavy use of narcotic drugs, psychotropic drugs, volatile organic solvents, etc.)\n14. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the study;\n15. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;\n16. Currently participating in other vaccine or drug clinical trials, or plan to participate in other clinical trials during the study;\n17. Receipt of live-attenuated vaccines within 14 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;\n18. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended vaccination site that may interfere with drug administration or observation of local reactions;\n19. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;\n20. Any other factors considered by the investigator to make the participant unsuitable for participation in the study","59 Years",{"count":308,"type":22},120,[217],"To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.",[287],[194,289],{"date":314,"type":40},"2025-07-09",{"date":316,"type":22},"2025-07-28",{"date":318,"type":22},"2026-01-15",{"name":46,"class":47},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":16,"sex":17,"minAge":281,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":337,"locationsCount":178},"100597238","phase-3-immunogenicity-and-safety-of-rabies-vaccine-serum-free-vero-cell-in-a-simulated-post-exposure-prophylaxis-regimen-100597238","NCT07055893","Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen","Immunogenicity and Safety of a Rabies Vaccine (Serum-free Vero Cell), Freeze-dried in Comparison With Verorab®, in a Simulated Post-exposure Prophylaxis Regimen in Healthy Populations Aged ≥1 Years: A Randomized, Double-Blind, Active-controlled Phase Ⅲ Clinical Trial","Inclusion Criteria:\n\n1. Populations aged ≥1 years old;\n2. Participants and\u002For participants' parents\u002Flegal guardians are able to understand and sign the informed consent form (ICF) voluntarily;\n3. Participants are able to comply with the study procedures based on the investigator's assessment;\n4. In a stable health status (defined as a stable preexisting disease status during the past 3 months, i.e., no change in treatment or hospitalization due to exacerbation of preexisting diseases);\n5. Participants were tested negative for HIV, Syphilis, Hepatitis B, Hepatitis C infection at the screening of this study (the test result should be provided);\n6. Female participants aged ≥15 years old with childbearing potential were tested negative for urine pregnancy test pre-vaccination, and also need to have effective contraceptive measures in the previous 2 weeks pre-vaccination.\n7. Participants of childbearing potential and their partners are willing to take effective contraceptive measures and have no sperm or ovum donation plan from the time of signing ICF to 28 days after the last dose of vaccination;\n8. Participants should provide verifiable identifications, and contact or be contacted with the investigators during the study period\n\nExclusion Criteria:\n\n1. Fever on vaccination day, with axillary temperature \\>37.0°C (aged ≥5 years old) or \\>37.3°C (aged 1\\~4 years old) pre-vaccination;\n2. Previous vaccination against rabies (in pre- or post-exposure regimen) with either trial vaccines or licensed vaccines;\n3. Previous administration with rabies immunoglobulins or monoclonal antibodies;\n4. Bite by, or exposure to a potentially rabid animal in the previous 12 months with category Ⅱ or Ⅲ exposures;\n5. Female participants who are currently lactating or pregnant;\n6. Known serious allergy to vaccines or vaccine ingredients, such as severe urticaria, anaphylactic shock, allergic laryngeal edema, allergic purpura, or known other serious adverse reactions to vaccine;\n7. With severe congenital malformations or developmental disorders, genetic defects, severe malnutrition;\n8. With autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n9. With poor controlled chronic illnesses or history of severe diseases, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, a history of major organ transplantation, drug-uncontrolled hypertension (only for participants aged ≥18 years old: with systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg), or any other disease or medical condition that the investigator believes could interfere with the trial results;\n10. With current or past history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding history of febrile seizures\\]) or psychiatric disorders, or presence of a family history of psychiatric disorders;\n11. With coagulation disorders (eg. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;\n12. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment in this study;\n13. With long-term alcohol abuse \\[\\>14 drinks per week (1 drink =14 g 100% alcohol =360 mL beer, or 150 mL wine, or 45 mL distilled liquor\u002Fliquor)\\] or substance abuse (repeated and heavy use of narcotic drugs, psychotropic drugs, volatile organic solvents, etc.)\n14. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the study;\n15. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;\n16. Currently participating in other vaccine or drug clinical trials, or plan to participate in other clinical trials during the study;\n17. Receipt of live-attenuated vaccines within 14 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;\n18. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended vaccination site that may interfere with drug administration or observation of local reactions;\n19. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;\n20. Any other factors considered by the investigator to make the participant unsuitable for participation in the study",{"count":283,"type":22},[25],"To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the pediatric and adult population in a PEP schedule",[192],[194,289,332],"post-exposure prophylaxis",{"date":314,"type":40},{"date":295,"type":22},{"date":336,"type":22},"2027-01-30",{"name":46,"class":47},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100572558","phase-3-efficacy-safety-and-immunogenicity-of-the-bivalent-inactivated-enterovirus-vaccine-vero-cell-100572558","NCT06734832","Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)","A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Trial on the Efficacy, Safety, and Immunogenicity of the Bivalent Enterovirus Inactivated Vaccine (Vero Cell) in Children Aged 6 to 71 Months.","Inclusion Criteria:\n\n* Healthy children aged 6 to 71 months with no history of EV71 vaccination; or healthy children aged 24 to 71 months who have completed two doses of EV71 vaccine at least 6 months prior.\n* Guardians who can understand and voluntarily sign the informed consent form.\n* Willing and able to comply with all visit schedules, sample collections, vaccinations, and other research procedures.\n* Provide proof of identity documents.\n\nExclusion Criteria:\n\n* A known history of HFMD\u002FHA.\n* Uncontrolled chronic diseases or a history of severe illnesses, including but not limited to cardiovascular diseases, blood disorders, liver or kidney diseases, digestive system diseases, respiratory system diseases, malignant tumors, or a history of major functional organ transplantation.\n* Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection).\n* Abnormal coagulation function (such as coagulation factor deficiencies, and platelet abnormalities).\n* Suffering from\u002Fhaving a history of severe neurological diseases (epilepsy, convulsions, or seizures \\[excluding a history of febrile seizures\\]) psychiatric disorders, or a family history of psychiatric disorders.\n* Various acute diseases or exacerbations of chronic diseases within the last 3 days, or known or suspected active infections.\n* Received a vaccine containing CA16 components.\n* Received immunosuppressive or other immunomodulatory treatments for ≥14 days within the past 6 months (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent; local or inhaled corticosteroids excluded), cytotoxic therapy, or planning to receive such treatment during the trial.\n* Received immunoglobulin or other blood products within the past 6 months, or planning to receive such treatment during the trial.\n* Received other investigational drugs or vaccines within the past 30 days, or planning to receive such drugs or vaccines during the trial.\n* Received live attenuated vaccines or nucleic acid vaccines within the past 14 days, or subunit or inactivated vaccines within the past 7 days.\n* Known allergy to any component of the investigational vaccine (inactivated EV71 virus, inactivated CA16 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, injectable water).\n* On the day of the planned vaccination with the trial vaccine, there is a fever, with axillary temperature \\> 37.0°C before vaccination;\n* On the day of the planned vaccination with the trial vaccine, the physical examination is not qualified.\n* Skin damage, inflammation, ulcers, rash, or scars at the target injection site that may interfere with vaccination or observation of local reactions.\n* According to the investigator's judgment, participants have any other factors that make them unsuitable for participation in the clinical trial.",{"count":346,"type":22},8000,[25],"This multicenter, randomized, double-blind, controlled Phase III clinical trial aims to evaluate the efficacy, safety, and immunogenicity of the bivalent enterovirus-inactivated vaccine (Vero cell) in healthy children aged 6 to 71 months.\n\nThe main questions it aims to answer are:\n\n* The primary vaccine efficacy of the investigational vaccine against Hand, Foot, and Mouth Disease（HFMD) caused by CA16 infection compared to the control vaccine.\n* The neutralizing antibody levels against EV71 in the trial group are non-inferior to those in the control group after two doses of vaccination.\n\nResearchers will compare the bivalent enterovirus-inactivated vaccine (Vero cell) to the EV71-inactivated vaccine (Vero cell) to prevent HFMD and Herpangina(HA).\n\nParticipants will be randomly assigned to the trial group and the control group in a 1:1 ratio to receive two doses of the investigational vaccine or the control EV71 vaccine, with a one-month interval between doses.",[350],"Hand, Foot, and Mouth Disease（HFMD)",[352,353,354,355,356,357,358,34],"bivalent enterovirus inactivated vaccine","Hand, Foot, and Mouth Disease","EV71","CA16","PHASE Ⅲ","vaccine efficacy","immonogenicity","2024-12-31",{"date":361,"type":40},"2025-01-01",{"date":363,"type":40},"2024-12-13",{"date":365,"type":22},"2026-11-30",{"name":46,"class":47},4,""]